Stock NOX NOXOPHARM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Noxopharm Limited

Equities

NOX

AU000000NOX9

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 11:37:34 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.064 AUD +4.92% Intraday chart for Noxopharm Limited +6.67% -9.86%
Apr. 04 Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug MT
Feb. 27 Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive MT

Valuation

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Capitalization 1 74.36 58.24 35.18 185.9 56.99 12.57
Enterprise Value (EV) 1 65.03 59.26 33.08 159.5 43.14 9.558
P/E ratio -3.51 x -5.16 x -82.5 x -18.2 x -3.04 x -0.83 x
Yield - - - - - -
Capitalization / Revenue 81.1 x 15.5 x 4.22 x 33.1 x 10.5 x 2.09 x
EV / Revenue 70.9 x 15.8 x 3.97 x 28.4 x 7.95 x 1.59 x
EV / EBITDA -6.83 x -5 x -4.2 x -11 x -4.53 x -0.91 x
EV / FCF 22.7 x -12.7 x -3.12 x -32.2 x -4.23 x -1.37 x
FCF Yield 4.4% -7.86% -32.1% -3.11% -23.6% -73.2%
Price to Book 7.33 x -579 x 2.73 x 4.56 x 2.36 x 1.38 x
Nbr of stocks (in thousands) 121,901 122,601 213,201 288,222 292,238 292,238
Reference price 2 0.6100 0.4750 0.1650 0.6450 0.1950 0.0430
Announcement Date 8/30/18 8/29/19 8/31/20 8/26/21 8/25/22 8/31/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Net sales 1 0.9165 3.751 8.332 5.608 5.429 6.01
EBITDA 1 -9.525 -11.85 -7.868 -14.54 -9.518 -10.49
EBIT 1 -9.584 -11.91 -8.034 -14.59 -9.779 -10.64
Operating Margin -1,045.69% -317.63% -96.42% -260.22% -180.14% -177.12%
Earnings before Tax (EBT) 1 -18.32 -12.57 -0.9996 -9.347 -18.67 -15.06
Net income 1 -18.28 -11.22 -0.2721 -9.347 -18.67 -15.06
Net margin -1,994.85% -299.22% -3.27% -166.66% -343.86% -250.52%
EPS 2 -0.1739 -0.0920 -0.002000 -0.0354 -0.0641 -0.0515
Free Cash Flow 1 2.864 -4.658 -10.61 -4.956 -10.19 -6.998
FCF margin 312.52% -124.18% -127.35% -88.37% -187.8% -116.44%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/30/18 8/29/19 8/31/20 8/26/21 8/25/22 8/31/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - 1.02 - - - -
Net Cash position 1 9.33 - 2.1 26.4 13.9 3.01
Leverage (Debt/EBITDA) - -0.0861 x - - - -
Free Cash Flow 1 2.86 -4.66 -10.6 -4.96 -10.2 -7
ROE (net income / shareholders' equity) -290% -289% -17.5% -34.8% -57.5% -90.7%
ROA (Net income/ Total Assets) -68.9% -79% -41.2% -26.9% -16.4% -36.2%
Assets 1 26.52 14.21 0.6602 34.8 113.7 41.55
Book Value Per Share 2 0.0800 -0 0.0600 0.1400 0.0800 0.0300
Cash Flow per Share 2 0.1000 0.0200 0.0300 0.0900 0.0500 0.0100
Capex 1 0.31 0.01 0 - - -
Capex / Sales 34.08% 0.17% 0.04% - - -
Announcement Date 8/30/18 8/29/19 8/31/20 8/26/21 8/25/22 8/31/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
NOXOPHARM LIMITED Stock Noxopharm Limited
-9.86% 12.2M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. NOX Stock
  4. Financials Noxopharm Limited